NEW YORK (GenomeWeb) – Curetis today announced licensing and distribution deals with Singaporean contract research organization Acumen Research Laboratories. 

Under the terms of the non-exclusive licensing deal, Curetis has obtained the worldwide rights to AcuSept, a biomarker panel for sepsis. The partners will jointly develop and clinically validate the panel as a sepsis host response test on Curetis' Unyvero molecular diagnostics platform. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

In Science this week: environmental DNA can help in studies of marine animals, and more.

Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.